Breast tumor targeting with 99mTc-HYNIC-PR81 complex as a new biologic radiopharmaceutical
- 31 October 2008
- journal article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 35 (7), 763-768
- https://doi.org/10.1016/j.nucmedbio.2008.07.002
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Targeted Therapy of Cancer: New Prospects for Antibodies and ImmunoconjugatesCA: A Cancer Journal for Clinicians, 2006
- A New Competitive Enzyme Linked Immunosorbent Assay (MRP83‐CA15‐3) for MUC1 Measurement in Breast CancerJournal of Immunoassay and Immunochemistry, 2006
- Production of Monoclonal Antibody, PR81, Recognizing the Tandem Repeat Region of MUC1 MucinHybridoma and Hybridomics, 2003
- Monoclonal Antibody Radiopharmaceuticals: Cationization, Pegylation, Radiometal Chelation, Pharmacokinetics, and Tumor ImagingBioconjugate Chemistry, 2003
- Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990–1999Breast Cancer Research, 2002
- Ca 15-3 in the follow-up of localised breast cancer: a prospective studyEuropean Journal Of Cancer, 2002
- Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PETNuclear Medicine and Biology, 2001
- MUC1 and cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1999
- Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 MucinTumor Biology, 1998
- Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapyCancer Immunology, Immunotherapy, 1997